Home > Insider Trading > Filing (0001140361-13-034588)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1311596	Regado Biosciences Inc	RGDO	Pharmaceutical Preparations (2834)	030422069

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1578307	Raphael Wisniewski	120 Mountain View Boulevard Basking Ridge NJ 07920		Yes	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock, Par Value $0.001 Per Share	Acquisiton	2013-08-27	1,021,930	$0.00	1,021,930	No	4	C	Indirect	See Footnote 4
Common Stock, Par Value $0.001 Per Share	Acquisiton	2013-08-27	169,633	$0.00	1,191,563	No	4	C	Indirect	See Footnote 4
Common Stock, Par Value $0.001 Per Share	Acquisiton	2013-08-27	1,215,708	$4.00	2,407,271	No	4	P	Indirect	See Footnote 4

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Footnote 4
No	4	C	Indirect	See Footnote 4
No	4	P	Indirect	See Footnote 4

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock, Par Value $0.001 Per Share	Stock Option (right to buy)	Acquisiton	2023-08-27	17,964	$0.00	17,964	$4.00
Common Stock, Par Value $0.001 Per Share	Series D Preferred Stock	Disposition	2013-08-27	17,066,243	$0.00	1,021,930	$0.00
Common Stock, Par Value $0.001 Per Share	Series E Preferred Stock	Disposition	2013-08-27	2,832,872	$0.00	169,633	$0.00

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
17,964	2013-08-27	No	4	A	Direct
0		No	4	C	Indirect
0		No	4	C	Indirect

Footnotes

100% of the shares underlying the option will vest on the one-year anniversary of the date of grant.
The shares of Series D Preferred Stock had no expiration date and automatically converted upon the consummation of the initial public offering of Regado Biosciences, Inc. (the "Company") at a conversion ratio of 1 share of Series D Preferred Stock to 0.05988024 shares of common stock, for no additional consideration.
The shares of Series E Preferred Stock had no expiration date and automatically converted upon the consummation of the Company's initial public offering at a conversion ratio of 1 share of Series E Preferred Stock to 0.05988024 shares of common stock, for no additional consideration.
The reportable securities are directly held by BioDiscovery 3, FCPR ("BioDiscovery") and indirectly held by Edmond de Rothschild Investment Partners ("Edmond de Rothschild"), BioDiscovery's management company. The Reporting Person is a partner at Edmond de Rothschild. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.